Hepatitis B (HBV) and Hepatitis C (HCV) are viral infections that cause inflammation of the liver. In Philadelphia, it is estimated that approximately 20,000 and 45,000 residents are living with Hepatitis B and C, respectively. Transmission of Hepatitis B and C can occur through blood, semen, and vaginal fluids. Common symptoms of acute infection include jaundice, dark urine, clay-colored stool, abdominal pain, and fatigue. Oftentimes, people with Hepatitis B and C are asymptomatic, making it difficult to diagnose and treat infection. If left untreated, both HBV and HCV can develop into chronic infection with long-term health outcomes such as liver cancer, cirrhosis, and death.
The Philadelphia Department of Public Health (PDPH) Division of Disease Control (DDC) publishes quarterly reports on the number of newly reported HBV and HCV cases in the City of Philadelphia.
Posting of this data is intended for the sole purpose of promoting the health of Philadelphia residents. PDPH attempts to post accurate and reliable information, but does not guarantee that the surveillance data is complete or up-to-date. PDPH assumes no responsibility for any errors, omissions or other discrepancies in these electronically posted files. Information from this site may not be copyrighted, nor used for commercial purposes.
The following graphs and tables depict selected aggregate results of PDPH’s newly reported HBV and HCV acute and chronic infections.
Overview of Hepatitis B & C Case Counts
Number of Newly Reported Viral Hepatitis Cases Reported to PDPH, January - December, 2016
(Confirmed & Probable)
*Acute - includes newly reported cases confirmed as acute according to CDC case definition
(Note that since the majority of acute Hepatitis C infections are asymptomatic they remain undetected by passive surveillance)
**Chronic - includes newly reported cases with an HCV antibody positive result and no reported RNA result.
Hepatitis B Cases
Hepatitis C Cases
The following graphs represent findings from PDPH’s enhanced hepatitis surveillance program (2013 – Q3 2016). Approximately one third of all newly reported HBV cases and one fourth of all newly reported HCV cases are contacted to obtain supplemental clinical and risk factor information about their disease.